About 65,500 results
Open links in new tab
  1. 340B Drug Pricing Program | HRSA

    The 340B Program enables covered entities to stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services. Manufacturers …

  2. 340B Eligibility | HRSA

    Discover eligibility and registration details for HRSA's 340B Drug Pricing Program to help entities access discounted medications

  3. 340B Educational Resources | HRSA

    Our website provides resources to help 340B Program stakeholders with navigating the 340B Program, including registration and implementation, requirements compliance, program integrity, and more:

  4. Program Requirements | HRSA

    To purchase drugs at the 340B price, covered entities must continue to meet the requirements of the 340B Drug Pricing Program.

  5. HRSA Announces Application Process for the 340B Rebate Model Pilot ...

    Jul 31, 2025 · Today, the Health Resources and Services Administration (HRSA) announced the availability of a voluntary 340B Rebate Model Pilot Program for drugs on the CMS Medicare Drug …

  6. 340B-Search Covered Entities

    An official website of the United States government Here's how you know About 340B OPAIS Home Search Reports

  7. 340B Rebate Model Pilot Program | HRSA

    The 340B Rebate Model Pilot Program consists of a selected group of drugs of manufacturers who have submitted plans meeting specific criteria that HRSA has approved.

  8. 340B Office of Pharmacy Affairs Information System | HRSA

    The 340B registration and pricing databases are known as the 340B Office of Pharmacy Affairs Information System (340B OPAIS). Authorized users of 340B OPAIS must have a user account with …

  9. Contract Pharmacy Services | HRSA

    A contract pharmacy must register for the 340B Program and ensure compliance with all 340B Program requirements before giving out 340B drugs for a covered entity.

  10. FAQs | HRSA

    Which manufacturers and drugs are subject to 340B pricing, and can participating manufacturers offer only a subset of the drugs they manufacture at 340B prices?